Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
Open Access
- 1 April 2021
- journal article
- research article
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 10 (5), 393-407
- https://doi.org/10.2217/cer-2020-0276
Abstract
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK + oral AD versus oral AD + PBO over 52 weeks from multiple US payer perspectives. Clinical end points and cost inputs were derived from clinical trials and the literature, respectively. Results: Under the base-case scenario, the cost-per-remitter for ESK + oral AD and oral AD + PBO were as follows: Commercial: US$85,808 versus US$100,198; Medicaid: US$76,236 versus US$96,067; Veteran’s Affairs: US$77,765 versus US$104,519; and Integrated Delivery Network: US$103,924 versus US$142,766. Conclusion: The findings suggest that ESK + oral AD is a cost-efficient alternative treatment for treatment-resistant depression compared with oral AD + PBO.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive DisorderBritish Journal of Psychology, 2015
- Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to AntidepressantsBritish Journal of Psychology, 2015
- A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013Psychiatric Services, 2014
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010The Lancet, 2012
- A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depressionThe World Journal of Biological Psychiatry, 2011
- Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorderCurrent Medical Research and Opinion, 2010
- Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class SwitchesBiological Psychiatry, 2008
- Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trialsThe British Journal of Psychiatry, 2007
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006
- Olanzapine/Fluoxetine Combination for Treatment-Resistant DepressionBritish Journal of Psychology, 2005